{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-050060","form_type":"8-K","ticker":"ADTX","cik":"0001726711","company_name":"Aditxt, Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.487719+00:00","generated_at":"2026-05-20T03:01:40.970580+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aditxt reiterates Sept 2025 close target for Evofem deal; Evofem had $19.5M revenue, first ex-US deal signed","bullets":["Acquisition of Evofem targeted to close by September 2025; conditions include resolving senior creditor and Evofem shareholder vote.","Evofem generated $19.5M net revenue last year; has two FDA-approved products (Phexxi, Solosec) and signed first ex-US deal with Pharma 1 in Middle East.","New manufacturer Lee Pharma committed to lowering Evofem's COGS by over 50% to mitigate tariff volatility and support European expansion.","Pearsanta's endometriosis/ovarian cancer diagnostic platform expected near revenue in Q4 2025; Adimune autoimmune program targets regulatory filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-050060","json":"https://secwatch.observer/filing/0001213900-25-050060.json","markdown":"https://secwatch.observer/filing/0001213900-25-050060.md","text":"https://secwatch.observer/filing/0001213900-25-050060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726711/000121390025050060/0001213900-25-050060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726711/000121390025050060/ea0244325-8k_aditxt.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T03:01:40.970580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}